All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Currently, there is no one standard of care for first-line treatment of patients with chronic graft-versus-host disease (cGvHD) who do not respond to steroids.1 There is evidence to support the use of rituximab, a chimeric anti-CD20 antibody (when administrated weekly at a dose of 375 mg/ m2), as an adequate treatment option; however, it is not cost-effective.1
Here, we summarize key findings by Colunga-Pedraza et al.1 in Transplant Immunology on the use of low-dose rituximab in steroid-refractory cGvHD (SR-cGvHD).
Table 1. Overall survival in patients with and without rituximab treatment*
Overall survival, % |
1-year |
2-years |
3-years |
Among patients with cGvHD |
83 |
78 |
58 |
Among patients with cGvHD following rituximab |
81 |
78 |
60 |
cGvHD, chronic graft-versus-host-disease; OS, overall survival. |
Key learnings1 |
|
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox